SEARCH

SEARCH BY CITATION

References

  • 1
    Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:21212158.
  • 2
    Chobanian AV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:25602572.
  • 3
    Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 4
    Medical research council trial of treatment of mild hypertension: principal results. MRC working party. BMJ. 1985;291:97104.
  • 5
    Management Committee. The Australian therapeutic trial in mild hypertension. Lancet. 1980;1:12611267.
  • 6
    Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mortality in “mild” hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med. 1982;307:976980.
  • 7
    Liu L, Zhang Y, Liu G, et al; FEVER Study Group. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:21572172.
  • 8
    Schrier RW, Eslacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria retinopathy and strokes. Kidney Int. 2002;61:10881097.
  • 9
    Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet. 2000;353:253259.
  • 10
    ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet. 2007;370:829840.
  • 11
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2002;342:145153.
  • 12
    Nissen SE, Tuzco EM, Libby P, et al; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study – a randomized controlled trial. JAMA. 2004;292:22172225.
  • 13
    PROGRESS Collaborative Study Group. Randomized trial of perindopril-based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358:10331041.
  • 14
    Arima H, Chalmers J, Woodward M, et al., for the PROGRESS collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:12011208.
  • 15
    Yusuf S, Diener HC, Sacco RL, et al; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:12251237.
  • 16
    Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009;27:923934.
  • 17
    Amery A, Birkenhäger W, Brisko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:13491354.
  • 18
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:32553264.
  • 19
    MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405412.
  • 20
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998;351:17551762.
  • 21
    Toumilehto J, Rastenyte D, Birkenhäger WH, et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340:677684.
  • 22
    Brenner BM, Cooper ME, De Zeeuw D, et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861869.
  • 23
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:20492051.
  • 24
    Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the international Verapamil SR-Trandolapril Study. Hypertension. 2007;50:299305.
  • 25
    Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884893.
  • 26
    Lewington S, Clarke R, Qizilbash N, et al., for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:19031913.
  • 27
    Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99:2133.
  • 28
    Jamerson K, Weber MA, Bakris GL, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:24172428.
  • 29
    Mann JF, Schmeider RE, McQueen M, et al., ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet. 2008;372:547553.
  • 30
    Giles TD, Materson BJ, Cohn JN, et al. Definition and classification of hypertension: an update. J Clin Hypertens (Greenwich). 2009;11:611614.